Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Minalrestat(ARI-509) 是一种具有口服活性和有效性的醛糖还原酶 (aldose reductase) 抑制剂,可用于研究糖尿病患者微血管反应性受损。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,780 | 现货 | ||
5 mg | ¥ 4,480 | 现货 | ||
10 mg | ¥ 6,380 | 现货 | ||
25 mg | ¥ 9,620 | 现货 | ||
50 mg | ¥ 12,900 | 现货 |
产品描述 | Minalrestat(ARI-509) is an orally active and potent aldose reductase inhibitor for the study of impaired microvascular reactivity in diabetic patients. |
体外活性 |
Minalrestat (100 μM) reduces intracellular sorbitol content in primary cultured rat cells without affecting intracellular glucose levels.[3] Minalrestat (100 μM, 48 h) causes the accumulation of PKC-α and -β2 in primary cultured rat mesangial cells.[3] |
体内活性 | The diabetic group was treated from 3 days after the alloxan injection with Minalrestat (10 mg/kg/day) for 30 days and the Minalrestat treatment (10 mg/kg/day/7 days) of galactosemic rats started concomitantly with the induction of galactosemia. The impaired responses to bradykinin, histamine, and platelet-activating factors of arterioles and venules observed in diabetic and galactosemic rats were completely prevented by Minalrestat. Neither diabetes nor galactosemia affected responses to acetylcholine and sodium nitroprusside. Responses to these agents were not modified by aldose reductase inhibition. The restoring effect of Minalrestat was reversed by inhibition of nitric oxide (NO) synthesis with N(omega)-nitro-L-arginine methyl ester, by blocking K(+) channel with tetraethylammonium but not by cyclooxygenase inhibition with diclofenac.[1] |
别名 | ARI509, WAY-121509, WAY121509, WAYARI-509, ARI-509, WAY-ARI-509 |
分子量 | 449.2 |
分子式 | C19H11BrF2N2O4 |
CAS No. | 129688-50-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (100.18 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2262 mL | 11.1309 mL | 22.2618 mL | 55.6545 mL |
5 mM | 0.4452 mL | 2.2262 mL | 4.4524 mL | 11.1309 mL | |
10 mM | 0.2226 mL | 1.1131 mL | 2.2262 mL | 5.5654 mL | |
20 mM | 0.1113 mL | 0.5565 mL | 1.1131 mL | 2.7827 mL | |
50 mM | 0.0445 mL | 0.2226 mL | 0.4452 mL | 1.1131 mL | |
100 mM | 0.0223 mL | 0.1113 mL | 0.2226 mL | 0.5565 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Minalrestat 129688-50-2 Endocrinology/Hormones Metabolism Reductase ARI509 WAY-121509 ARI 509 WAY-ARI509 WAY-ARI 509 WAY121509 WAYARI 509 WAYARI-509 WAY 121509 ARI-509 WAYARI509 WAY-ARI-509 Inhibitor inhibitor inhibit